Cloning and Characterization of the Full-Length cDNA of Rabies Virus Oral Vaccine Strain SRV_9
Tiedong Wang
Abstract
Tiedong Wang
Abstract
In order to obtain a more complete understanding of oral rabies vaccine candidate strain SRV_9, three cDNA fragments covering the complete genome were obtained by RT-PCR,they were cloned into pMD-18T vector separately and sequenced, the full-length cDNA of Rabies Virus Oral Vaccine Strain SRV_9 was determined(GenBank(Accession No AF499686).The glycoprotein of SRV_9 was compared both with its ancestor SAD B19 and other strains: 3aG,ERA,CVS,etc. The results indicated that there were three amino acid differences in the antigenic site between the vaccine strain SRV_9 and other virus, the 34rd amino acid in antigenic site Ⅱfrom Gly to Glu, the 333rd amino acid in antigenic site Ⅲ from Arg to Ser, the 338rd amino acid in antigenic site Ⅲ from Ile to Val. These mutations may contribute to the attenuation of the virulence and its stability.The sequence analysis would aid in understanding the mechanism of the vaccine?
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In order to obtain a more complete understanding of oral rabies vaccine candidate strain SRV_9, three cDNA fragments covering the complete genome were obtained by RT-PCR,they were cloned into pMD-18T vector separately and sequenced, the full-length cDNA of Rabies Virus Oral Vaccine Strain SRV_9 was determined(GenBank(Accession No AF499686).The glycoprotein of SRV_9 was compared both with its ancestor SAD B19 and other strains: 3aG,ERA,CVS,etc. The results indicated that there were three amino acid differences in the antigenic site between the vaccine strain SRV_9 and other virus, the 34rd amino acid in antigenic site Ⅱfrom Gly to Glu, the 333rd amino acid in antigenic site Ⅲ from Arg to Ser, the 338rd amino acid in antigenic site Ⅲ from Ile to Val. These mutations may contribute to the attenuation of the virulence and its stability.The sequence analysis would aid in understanding the mechanism of the vaccine?
Key concepts: Virology, Complementary DNA, GenBank, Biology, Rabies virus, Amino acid, Virulence, Virus